Company profilePharmaceutical#212 of 1,318 in Pakistan1 DRAP alert

Medifine Laboratories (Pvt) Ltd.

Pharmaceutical company · 86 brands · 76 molecules

Ranked #53 of 207 companies in Quinolone Antibacterials

86 registered products 53 pharmaceutical brands 76 distinct molecules 1 DRAP alert

Company overview

86
registered products
53
pharmaceutical brands
76
distinct molecules
12
therapeutic classes
1
DRAP alerts

Medifine Laboratories (Pvt) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 86 product registrations across 76 distinct molecules. Its portfolio is concentrated in Quinolone Antibacterials and Antiinflammatory And Antirheumatic Products. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Medifine

40 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

39
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202539

Top molecules by brand count

Levofloxacin7 brands
Diazepam6 brands
Amlodipine5 brands
Cefixime5 brands
Risperidone4 brands
Omeprazole4 brands
Ceftriaxone4 brands
Montelukast3 brands
Moxifloxacin3 brands

Therapeutic classes

Quinolone Antibacterials · 4Antiinflammatory And Antirheumatic Products · 4Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 3Other Beta-Lactam, Cephalosporins & Penems · 3Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 3Muscle Relaxant · 2Macrolides, Lincosamides And Streptogramins · 2Antianemic, Iron Preparations · 1Respiratory Care · 1Drugs For Obstructive Airway Diseases, Systemic · 1Vitamin A, D & Combinations · 1Vitamin C · 1

Conditions treated

Asthma/Allergy · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official77 products · Rs 35.28 – Rs 2,728.91
DVAGO1 products · Rs 1,475 – Rs 1,475
Servaid1 products · Rs 294.98 – Rs 294.98
Median across source: Rs 386.12

Regulatory record

1 alert in the DRAP feed we track.

Drug Safety Alert: Potential Risk of Abuse, Dependence and Withdrawal with Benzodiazepines
2023-04-11

Competitive set

Companies whose registered portfolio overlaps most with this one.

NEUTRO PHARMA (PVT) LTD.34 shared molecules
BIO LABS (PVT) LTD.33 shared molecules
HIGH - Q INTERNATIONAL32 shared molecules
FRIENDS PHARMA (PVT) LTD32 shared molecules
MEDISAVE PHARMACEUTICALS30 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NEUTRO PHARMA (PVT) LTD. holds 111 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAmikacinAnastrazoleAnastrozole
BIO LABS (PVT) LTD. holds 124 molecules not in this portfolio
000 I.UAprepitantAremetherArtemetherArtesunateAscorbic Acid
HIGH - Q INTERNATIONAL holds 121 molecules not in this portfolio
000 I.UAcetyl L-CarnitineAmikacinAnastrozoleAprepitantArachis Oil

Get the full profile for Medifine

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.